Simcere Pharmaceutical Group has announced a Sponsored Research Agreement with Mass General Brigham. According to the agreement, up to eight research groups at Mass General Brigham will receive funding for select projects over a period of two years. The agreement will create a mutually beneficial partnership that advances research and creates new treatment options for cancer patients, autoimmune and central nervous system diseases. By teaming up with Mass General Brigham, Simcere gains access to the institution's cutting-edge research capabilities and leading clinical expertise. This collaboration is expected to enhance Simcere's global research and development (R&D) efforts, potentially accelerating the discovery and development of innovative therapies. The Sponsored Research Agreement between Simcere Pharmaceutical Group Limited and Mass General Brigham reflects the commitment in advancing drug development and fostering long-term partnerships. By collaborating with a renowned research institution like Mass General Brigham, Simcere aims to drive innovation and create new treatment options that can benefit patients globally.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!